熱門資訊> 正文
另外Therapeutics赢得Elevance Health保险协议
2026-06-25 20:02
- Plus Therapeutics (PSTV) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with Elevance Health (ELV) to expand coverage for a cancer screening test.
- The national agreement allows members of Elevance (ELV) to get reimbursed for CNSide, a test designed for patients with carcinomas and melanomas to identify whether their tumor cells have spread to the central nervous system.
- The laboratory-developed test known as the CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay is currently available to U.S. health care professionals exclusively through CNSide Diagnostics.
- The coverage decision, which took effect on May 1, 2026, is set to benefit roughly 45.4M people in the U.S., the company said, adding that the agreement widens its availability to 126M people based on total contracted lives.
More on Plus Therapeutics, Elevance Health
- Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)
- Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
- AI may help hospitals more than insurers, UBS says
- Elevance Health gains as Medicare sanctions risk abates
推薦文章
乾貨集錦！《跑贏美股》6月直播核心觀點總結
美股前瞻 | AI牛市不停！美光績后狂飆17%帶飛存儲板塊；美國5月核心PCE同比增3.4%；IBM推出全球首款小於1nm芯片
壓力測試過關 摩根大通、高盛等美國大型銀行提高股利並回購股份
華盛早報 | 美光盤后飆升近16%！炸裂財報引爆芯片股，納指期貨應聲漲2%；黃仁勛豪言AI進入盈利時代；高通全面進軍AI數據中心
港股概念追蹤 | 曝蘋果摺疊屏iPhone敲定7月底量產 產業鏈有望迎來高速發展拐點(附概念股)
美股前瞻 | AI風向標來襲！英偉達股東大會凌晨開始、美光財報盤后發佈；布油跌破75美元創戰后新低；海力士或7月10日登陸美股
拋售SpaceX，買入特斯拉？
資金覆盤 | 北水逆勢抄底港股近104億港元！加倉中芯國際、建滔集團，拋售阿里巴巴
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
